Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Rheumatoid Arthritis

  Free Subscription


Articles published in Clin Exp Rheumatol

Retrieve available abstracts of 192 articles:
HTML format
Text format



Single Articles


    November 2017
  1. NAGAI T, Matsueda Y, Tomita T, Yoshikawa H, et al
    The expression of mRNA for peptidylarginine deiminase type 2 and type 4 in bone marrow CD34+ cells in rheumatoid arthritis.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  2. THOMAS K, Flouri I, Repa A, Fragiadaki K, et al
    High 3-year golimumab survival in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: real world data from 328 patients.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


    October 2017
  3. MA MHY, Ibrahim F, Kingsley GH, Cope A, et al
    Variable impacts of different remission states on health-related quality of life in rheumatoid arthritis.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  4. POPE JE, Rampakakis E, Movahedi M, Cesta A, et al
    Treatment patterns in rheumatoid arthritis after discontinuation of methotrexate: data from the Ontario Best Practices Research Initiative (OBRI).
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  5. TWEEHUYSEN L, Schraa K, Netea MG, van den Hoogen FHJ, et al
    Ex-vivo inhibited cytokine profiling explains inferior treatment response to golimumab after adalimumab failure in rheumatoid arthritis.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


    September 2017
  6. BURSKA AN, Neilan J, Chisman RE, Pitaksalee R, et al
    Serum IL-7 as diagnostic biomarker for rheumatoid arthritis, validation with EULAR 2010 classification criteria.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  7. FERRO F, Elefante E, Luciano N, Talarico R, et al
    One year in review 2017: novelties in the treatment of rheumatoid arthritis.
    Clin Exp Rheumatol. 2017;35:721-734.
    PubMed     Text format     Abstract available


  8. CHUA JR, Gibson KA, Pincus T
    Pain and other self-report scores in patients with osteoarthritis indicate generally similar disease burden to patients with rheumatoid arthritis.
    Clin Exp Rheumatol. 2017;35 Suppl 107:88-93.
    PubMed     Text format     Abstract available


  9. MCWILLIAMS DF, Walsh DA
    Pain mechanisms in rheumatoid arthritis.
    Clin Exp Rheumatol. 2017;35 Suppl 107:94-101.
    PubMed     Text format     Abstract available


    August 2017
  10. SUN Y, Sun X, Liu Z, Wang X, et al
    MiR-338-5p suppresses rheumatoid arthritis synovial fibroblasts proliferation and invasion by targeting ADAMTS-9.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  11. SIEBUHR AS, Kjelgaard-Petersen CF, Sun S, Byrjalsen I, et al
    Suppression of active, but not total MMP-3, is associated with treatment response in a phase III clinical study of rheumatoid arthritis.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  12. MARTINEZ-ESTUPINAN L, Hernandez-Florez D, Janta I, Ovalles-Bonilla JG, et al
    An exploratory study to determine whether infliximab modifies levels of rheumatoid factor and antibodies to cyclic citrullinated peptides in rheumatoid arthritis patients.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  13. WEN W, Li Y, Cheng Y, He J, et al
    Lipopolysaccharide-binding protein is a sensitive disease activity biomarker for rheumatoid arthritis.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


    July 2017
  14. MANARA M, Caporali R, Favalli EG, Grosso V, et al
    Two-year retention rate of golimumab in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: data from the LORHEN registry.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  15. GIACOMELLI R, Ruscitti P, Bombardieri S, Cuomo G, et al
    What could we learn from the sub-analysis of a single nation cohort in a worldwide study? Lessons from the results observed in the Italian cohort of the GO-MORE trial.
    Clin Exp Rheumatol. 2017;35:623-629.
    PubMed     Text format     Abstract available


  16. PERTOVAARA M, Korpela M
    RAPID3 correlates with ESSPRI and other patient-reported outcomes in patients with primary Sjogren's syndrome.
    Clin Exp Rheumatol. 2017;35:718.
    PubMed     Text format     Abstract available


  17. BUSTAMENTE L, Matthieu B, Marquette CH, Roux C, et al
    Sarcoidosis and tocilizumab: is there a link?
    Clin Exp Rheumatol. 2017;35:716.
    PubMed     Text format     Abstract available


  18. QUARTUCCIO L, Mavragani CP, Nezos A, Gandolfo S, et al
    Type I interferon signature may influence the effect of belimumab on immunoglobulin levels, including rheumatoid factor in Sjogren's syndrome.
    Clin Exp Rheumatol. 2017;35:719-720.
    PubMed     Text format     Abstract available


  19. SFIKAKIS PP, Bournia VK, Sidiropoulos P, Boumpas DT, et al
    Biologic treatment for rheumatic disease: real-world big data analysis from the Greek country-wide prescription database.
    Clin Exp Rheumatol. 2017;35:579-585.
    PubMed     Text format     Abstract available


  20. SAIKI O, Uda H
    Successful extension of tocilizumab infusion intervals from 4 weeks to 6 or 5 weeks in 90% of RA patients with good response to 4-week intervals.
    Clin Exp Rheumatol. 2017;35:666-670.
    PubMed     Text format     Abstract available


    June 2017
  21. AYDIN SZ, Gunal EK, Ozata M, Keskin H, et al
    Six-joint ultrasound in rheumatoid arthritis: a feasible approach for implementing ultrasound in remission.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  22. LEON L, Gomez A, Vadillo C, Pato E, et al
    Severe adverse drug reactions to biological disease-modifying anti-rheumatic drugs in elderly patients with rheumatoid arthritis in clinical practice.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  23. BELL DA, Elhayek S, Cairns E, Barra L, et al
    Anti-homocitrullinated protein antibody isotype usage in rheumatoid arthritis and their unaffected first-degree relatives.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  24. MARRIE RA, Hitchon CA, Peschken CA, Chen H, et al
    Health care utilisation before and after intensive care unit admission in rheumatoid arthritis.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  25. MASI AT, Rehman AA, Jorgenson LC, Aldag JC, et al
    Preclinical biomarker associations with both incident rheumatoid arthritis and its subsequent mortality: sex effects in a 41-year, community-based, case-control cohort study.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  26. LESUIS N, van Vollenhoven RF, Akkermans RP, Verhoef LM, et al
    Rheumatologists' guideline adherence in rheumatoid arthritis: a randomised controlled study on electronic decision support, education and feedback.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


    May 2017
  27. HAMMER HB, Kvien TK, Terslev L
    Tenosynovitis in rheumatoid arthritis patients on biologic treatment: involvement and sensitivity to change compared to joint inflammation.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  28. DUQUENNE C, Wendling D, Sibilia J, Job-Deslandre C, et al
    Glucocorticoid-sparing effect of first-year anti-TNFalpha treatment in rheumatoid arthritis (CORPUS Cohort).
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  29. CAPORALI R, Idolazzi L, Bombardieri S, Ferraccioli G, et al
    Tocilizumab in the treatment of patients with rheumatoid arthritis in real clinical practice: results of an Italian observational study.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  30. SEBASTIANI M, Manfredi A, Cassone G, Sandri G, et al
    Interstitial lung disease is associated to infections of lower respiratory tract in immunocompromised rheumatoid arthritis patients.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  31. ACEBES C, Andreu JL, Balsa A, Battle E, et al
    Exploring the remission concept in rheumatoid arthritis with patients and rheumatologists: time for a new approach?
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  32. CODULLO V, Iannone F, Sinigaglia L, Favalli EG, et al
    Comparison of efficacy of first- versus second-line adalimumab in patients with rheumatoid arthritis: experience of the Italian biologics registries.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  33. GULLICK NJ, Mian AN, Ibrahim F, Walker D, et al
    Predicting responses in patients with rheumatoid arthritis to disease-modifying agents using baseline clinical data.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  34. RASHID T, Ebringer A, Wilson C
    The link between Proteus mirabilis, environmental factors and autoantibodies in rheumatoid arthritis.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  35. GADEHOLT O
    Rheumatoid arthritis is not a single disease.
    Clin Exp Rheumatol. 2017;35 Suppl 104:20-21.
    PubMed     Text format     Abstract available


  36. ANGELOTTI F, Parma A, Cafaro G, Capecchi R, et al
    One year in review 2017: pathogenesis of rheumatoid arthritis.
    Clin Exp Rheumatol. 2017;35:368-378.
    PubMed     Text format     Abstract available


  37. DANDA D, Sharma R, Truong D, Koelsch KA, et al
    Anti-La positive, anti-Ro negative subset of primary Sjogren's syndrome: anti-La is a reality but is the disease?
    Clin Exp Rheumatol. 2017;35:438-444.
    PubMed     Text format     Abstract available


  38. QUARTUCCIO L, Baldini C, Bartoloni E, Priori R, et al
    Correlation between ESSDAI and ClinESSDAI in a real-life cohort of patients with Sjogren's syndrome.
    Clin Exp Rheumatol. 2017;35:546-547.
    PubMed     Text format     Abstract available


  39. BALDUZZI S, Scire CA, Sakellariou G, Benaglio F, et al
    In early inflammatory polyarthritis more intensive management according to the 2010 ACR/EULAR criteria leads to higher rates of clinical remission: comparison of two cohorts treated according to different treat-to-target protocols.
    Clin Exp Rheumatol. 2017;35:401-405.
    PubMed     Text format     Abstract available


  40. GHIGGIA A, Torta R, Tesio V, Di Tella M, et al
    Psychosomatic syndromes in fibromyalgia.
    Clin Exp Rheumatol. 2017;35 Suppl 105:106-111.
    PubMed     Text format     Abstract available


  41. BARTON JC, Bertoli LF, Barton JC, Acton RT, et al
    Fibromyalgia in 300 adult index patients with primary immunodeficiency.
    Clin Exp Rheumatol. 2017;35 Suppl 105:68-73.
    PubMed     Text format     Abstract available


  42. TORRENTE-SEGARRA V, Corominas H, Sanchez-Piedra C, Fernandez-Castro M, et al
    Fibromyalgia prevalence and associated factors in primary Sjogren's syndrome patients in a large cohort from the Spanish Society of Rheumatology registry (SJOGRENSER).
    Clin Exp Rheumatol. 2017;35 Suppl 105:28-34.
    PubMed     Text format     Abstract available


    April 2017
  43. HARAOUI B, Casado G, Czirjak L, Taylor A, et al
    Patterns of tocilizumab use, effectiveness and safety in patients with rheumatoid arthritis: core data results from a set of multinational observational studies.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  44. FUKUYO S, Nakayamada S, Iwata S, Kubo S, et al
    Abatacept therapy reduces CD28+CXCR5+ follicular helper-like T cells in patients with rheumatoid arthritis.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


    March 2017
  45. TIEN YC, Yen HH, Chiu YM
    Incidence and clinical characteristics of hepatitis B virus reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for rheumatoid arthritis.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  46. KURIYA B, Schieir O, Lin D, Xiong J, et al
    Thresholds for the 28-joint disease activity score (DAS28) using C-reactive protein are lower compared to DAS28 using erythrocyte sedimentation rate in early rheumatoid arthritis.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  47. YANG M, Galebach PJ, Signorovitch JE, Garg V, et al
    Effectiveness and healthcare costs among stabilised rheumatoid arthritis patients with dose reduction of adalimumab or etanercept in real world.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  48. AVILA-RIBEIRO P, Brault Y, Dougados M, Gossec L, et al
    Psychometric properties of sleep and coping numeric rating scales in rheumatoid arthritis: a subanalysis of an etanercept trial.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  49. CAPORALI R, Carletto A, Conti F, D'Angelo S, et al
    Using a modified Delphi process to establish clinical consensus for the diagnosis, risk assessment and abatacept treatment in patients with aggressive rheumatoid arthritis.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  50. FERRO F, Marcucci E, Orlandi M, Baldini C, et al
    One year in review 2017: primary Sjogren's syndrome.
    Clin Exp Rheumatol. 2017;35:179-191.
    PubMed     Text format     Abstract available


  51. PERTOVAARA M, Parkkila S, Korpela M
    Anti-carbonic anhydrase autoantibodies and serum beta-2 microglobulin correlate with the ClinESSDAI score in patients with Sjogren's syndrome.
    Clin Exp Rheumatol. 2017;35:351.
    PubMed     Text format     Abstract available


  52. ARENDS S, Meiners PM, Moerman RV, Kroese FG, et al
    Physical fatigue characterises patient experience of primary Sjogren's syndrome.
    Clin Exp Rheumatol. 2017;35:255-261.
    PubMed     Text format     Abstract available


  53. HAACKE EA, van der Vegt B, Meiners PM, Vissink A, et al
    Abatacept treatment of patients with primary Sjogren's syndrome results in a decrease of germinal centres in salivary gland tissue.
    Clin Exp Rheumatol. 2017;35:317-320.
    PubMed     Text format     Abstract available


  54. LEE KE, Kang JH, Yim YR, Kim JE, et al
    Predictive significance of CCL21 and CXCL13 levels in the minor salivary glands of patients with Sjogren's syndrome.
    Clin Exp Rheumatol. 2017;35:234-240.
    PubMed     Text format     Abstract available


  55. GIUFFRA V, Minozzi S, Vitiello A, Fornaciari A, et al
    On the history of gout: paleopathological evidence from the Medici family of Florence.
    Clin Exp Rheumatol. 2017;35:321-326.
    PubMed     Text format     Abstract available


    February 2017
  56. CURTIS JR, Lee EB, Martin G, Mariette X, et al
    Analysis of non-melanoma skin cancer across the tofacitinib rheumatoid arthritis clinical programme.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  57. KIM HW, Kwon YJ, Park BW, Song JJ, et al
    Differential expressions of NOD-like receptors and their associations with inflammatory responses in rheumatoid arthritis.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  58. GANDIGA PC, George MD, Baker JF
    Choice of second biologic in rheumatoid arthritis patients with inadequate response to initial anti-TNF.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  59. PERROT S, Peixoto M, Dieude P, Hachulla E, et al
    Patient phenotypes in fibromyalgia comorbid with systemic sclerosis or rheumatoid arthritis: influence of diagnostic and screening tests. Screening with the FiRST questionnaire, diagnosis with the ACR1990 and revised ACR 2010 criteria.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


    January 2017
  60. NIKIPHOROU E, Galloway J, van Riel P, Yazici Y, et al
    The spectrum of early rheumatoid arthritis practice across the globe: results from a multinational cross sectional survey.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  61. LENERT A, Fardo DW
    Detecting novel micro RNAs in rheumatoid arthritis with gene-based association testing.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  62. NAGAFUCHI Y, Shoda H, Sumitomo S, Nakachi S, et al
    Enhanced gut homing receptor expression of unswitched memory B cells in rheumatoid arthritis.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  63. BAKER JF, Ostergaard M, Emery P, Baker DG, et al
    Development and validation of rheumatoid arthritis magnetic resonance imaging inflammation thresholds associated with lack of damage progression.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  64. ADDIMANDA O, Marino M, Farina I, Trevisani M, et al
    Diagnosis and treatment of rheumatoid arthritis in the Emilia Romagna region: a prospective population-based study.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  65. LAMPROPOULOS CE, Orfanos P, Manoussakis MN, Tzioufas AG, et al
    Treat-to-target biologic therapy in patients with rheumatoid arthritis is more efficacious and safe compared to delayed initiation of biologics: a real-world study.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  66. AYDIN SZ, Pay S, Inanc N, Kamali S, et al
    Which joints and why do rheumatologists scan in rheumatoid arthritis by ultrasonography? A real life experience.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  67. AMANN J, Wessels AM, Breitenfeldt F, Huscher D, et al
    Quantifying cutaneous adverse effects of systemic glucocorticoids in patients with rheumatoid arthritis: a cross-sectional cohort study.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  68. L'AMI MJ, Kneepkens EL, Nurmohamed MT, Krieckaert CL, et al
    Long-term treatment response in rheumatoid arthritis patients starting adalimumab or etanercept with or without concomitant methotrexate.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  69. PARK SK, Lee MY, Jang EJ, Kim HL, et al
    A comparison of discontinuation rates of tofacitinib and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and Bayesian network meta-analysis.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  70. KRUMBHOLZ G, Junker S, Meier FM, Rickert M, et al
    Response of human rheumatoid arthritis osteoblasts and osteoclasts to adiponectin.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  71. HU Y, Cui J, Sparks JA, Malspeis S, et al
    Circulating carotenoids and subsequent risk of rheumatoid arthritis in women.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  72. TOURNADRE A, Pereira B, Dubost JJ, Rincheval N, et al
    Management of dyslipidemia in high-risk patients with recent-onset rheumatoid arthritis: targets still not met despite specific recommendations. Results from the ESPOIR cohort during the first five years of follow-up.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  73. CURTIS JR, Schulze-Koops H, Takiya L, Mebus CA, et al
    Efficacy and safety of tofacitinib in older and younger patients with rheumatoid arthritis.
    Clin Exp Rheumatol. 2017.
    PubMed     Text format     Abstract available


  74. NICAISE C, Weichselbaum L, Schandene L, Gangji V, et al
    Phagocyte-specific S100A8/A9 is upregulated in primary Sjogren's syndrome and triggers the secretion of pro-inflammatory cytokines in vitro.
    Clin Exp Rheumatol. 2017;35:129-136.
    PubMed     Text format     Abstract available


  75. BIRT JA, Tan Y, Mozaffarian N
    Sjogren's syndrome: managed care data from a large United States population highlight real-world health care burden and lack of treatment options.
    Clin Exp Rheumatol. 2017;35:98-107.
    PubMed     Text format     Abstract available


  76. ATZENI F, Gianturco L, Colombo C, Ricci C, et al
    Can speckle tracking echocardiography detect subclinical left ventricular dysfunction in patients with primary Sjogren's syndrome?
    Clin Exp Rheumatol. 2017;35:173.
    PubMed     Text format     Abstract available


    December 2016
  77. CALVO-ALEN J, Monteagudo I, Salvador G, Vazquez-Rodriguez TR, et al
    Non-adherence to subcutaneous biological medication in patients with rheumatoid arthritis: a multicentre, non-interventional study.
    Clin Exp Rheumatol. 2016.
    PubMed     Text format     Abstract available


  78. KRAUSE C, Herborn G, Braun J, Rudolf H, et al
    Response to methotrexate predicts long-term mortality of patients with rheumatoid arthritis independent of the degree of response: results of a re-evaluation 30 years after baseline.
    Clin Exp Rheumatol. 2016.
    PubMed     Text format     Abstract available


  79. CECCARELLI F, Massafra U, Perricone C, Idolazzi L, et al
    Anti-TNF treatment response in rheumatoid arthritis patients with moderate disease activity: a prospective observational multicentre study (MODERATE).
    Clin Exp Rheumatol. 2016.
    PubMed     Text format     Abstract available


    November 2016
  80. MARTELLI-PALOMINO G, Paoliello-Paschoalato AB, Crispim JC, Rassi DM, et al
    DNA damage increase in peripheral neutrophils from patients with rheumatoid arthritis is associated with the disease activity and the presence of shared epitope.
    Clin Exp Rheumatol. 2016.
    PubMed     Text format     Abstract available


    October 2016
  81. DETORAKIS EE, Magkanas E, Lasithiotaki I, Sidiropoulos P, et al
    Evolution of imaging findings, laboratory and functional parameters in rheumatoid arthritis patients after one year of treatment with anti-TNF-alpha agents.
    Clin Exp Rheumatol. 2016.
    PubMed     Text format     Abstract available


  82. GIOLLO A, Viapiana O, Carletto A, Ortolani R, et al
    Rituximab increases peripheral natural killer cells in patients with rheumatoid arthritis.
    Clin Exp Rheumatol. 2016.
    PubMed     Text format     Abstract available


  83. URSINI F, D'Angelo S, Russo E, Arturi F, et al
    Serum complement C3 strongly correlates with whole-body insulin sensitivity in rheumatoid arthritis.
    Clin Exp Rheumatol. 2016.
    PubMed     Text format     Abstract available


  84. MASI AT, Rehman AA, Jorgenson LC, Aldag JC, et al
    Increased mortality of incident rheumatoid arthritis (RA) versus matched non-RA control subjects: a community-based long-term prospective cohort study.
    Clin Exp Rheumatol. 2016.
    PubMed     Text format     Abstract available


  85. RODRIGUEZ-RODRIGUEZ L, Leon L, Ivorra-Cortes J, Gomez A, et al
    Treatment in rheumatoid arthritis and mortality risk in clinical practice: the role of biologic agents.
    Clin Exp Rheumatol. 2016.
    PubMed     Text format     Abstract available


  86. GENTY M, Combe B, Kostine M, Ardouin E, et al
    Improvement of fatigue in patients with rheumatoid arthritis treated with biologics: relation with sleep disorders, depression and clinical efficacy. A prospective, multicentre study.
    Clin Exp Rheumatol. 2016.
    PubMed     Text format     Abstract available


  87. RAMIREZ J, Iniciarte-Mundo J, Cuervo A, Ruiz-Esquide V, et al
    Differing local and systemic inflammatory burden in polyarticular psoriatic arthritis and rheumatoid arthritis patients on anti-TNF treatment in clinical remission.
    Clin Exp Rheumatol. 2016.
    PubMed     Text format     Abstract available


  88. CUPPEN BV, Jacobs JW, Ter Borg EJ, Marijnissen AC, et al
    Necessity of TNF-alpha inhibitor discontinuation in rheumatoid arthritis is predicted by smoking and number of previously used biological DMARDs.
    Clin Exp Rheumatol. 2016.
    PubMed     Text format     Abstract available


  89. BOUBOUCHAIROPOULOU N, Flouri I, Drosos AA, Boki K, et al
    Treatment with the first TNF inhibitor in rheumatoid arthritis patients in the Hellenic Registry of Biologic Therapies improves quality of life especially in young patients with better baseline functional status.
    Clin Exp Rheumatol. 2016.
    PubMed     Text format     Abstract available


    September 2016
  90. CECCHETTI S, Tatar Z, Galan P, Pereira B, et al
    Prevalence of vitamin D deficiency in rheumatoid arthritis and association with disease activity and cardiovascular risk factors: data from the COMEDRA study.
    Clin Exp Rheumatol. 2016.
    PubMed     Text format     Abstract available


  91. HAMURYUDAN V, Direskeneli H, Ertenli I, Inanc M, et al
    Direct and indirect healthcare costs of rheumatoid arthritis patients in Turkey.
    Clin Exp Rheumatol. 2016.
    PubMed     Text format     Abstract available


  92. FISHER BA, Donatien P, Filer A, Winlove CP, et al
    Decrease in articular hypoxia and synovial blood flow at early time points following infliximab and etanercept treatment in rheumatoid arthritis.
    Clin Exp Rheumatol. 2016.
    PubMed     Text format     Abstract available


  93. JIANG M, Ren F, Zheng Y, Yan R, et al
    Efficacy and safety of down-titration versus continuation strategies of biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis with low disease activity or in remission: a systematic review and meta-analysis.
    Clin Exp Rheumatol. 2016.
    PubMed     Text format     Abstract available


  94. BELLUCCI E, Terenzi R, La Paglia GM, Gentileschi S, et al
    One year in review 2016: pathogenesis of rheumatoid arthritis.
    Clin Exp Rheumatol. 2016;34:793-801.
    PubMed     Text format     Abstract available


  95. BERGSTRA SA, Machado PM, van den Berg R, Landewe RB, et al
    Ten years of METEOR (an international rheumatoid arthritis registry): development, research opportunities and future perspectives.
    Clin Exp Rheumatol. 2016;34 Suppl 101:87-90.
    PubMed     Text format     Abstract available


  96. HETLAND ML, Krogh NS, Horslev-Petersen K, Schiottz-Christensen B, et al
    Using an electronic platform interactively to improve treatment outcome in patients with rheumatoid arthritis: new developments from the DANBIO registry.
    Clin Exp Rheumatol. 2016;34 Suppl 101:75-78.
    PubMed     Text format     Abstract available


  97. JACOBS JW
    The Computer Assisted Management in Early Rheumatoid Arthritis programme tool used in the CAMERA-I and CAMERA-II studies.
    Clin Exp Rheumatol. 2016;34 Suppl 101:69-72.
    PubMed     Text format     Abstract available


  98. VAN RIEL PL, Renskers L
    The Disease Activity Score (DAS) and the Disease Activity Score using 28 joint counts (DAS28) in the management of rheumatoid arthritis.
    Clin Exp Rheumatol. 2016;34 Suppl 101:40-44.
    PubMed     Text format     Abstract available


  99. SCHEINBERG M
    Is Etanar a new biologic?
    Clin Exp Rheumatol. 2016;34:954.
    PubMed     Text format     Abstract available


  100. HILLEN MR, Moret FM, Giovannone B, Kruize AA, et al
    Size matters: decreased glandular levels of anti-inflammatory short thymic stromal lymphopoietin in primary Sjogren's syndrome.
    Clin Exp Rheumatol. 2016;34:959-960.
    PubMed     Text format     Abstract available


  101. LAZAROU I, Kelly S, Humby F, Di Cicco M, et al
    Ultrasound-guided synovial biopsy of the wrist does not alter subsequent clinical or ultrasound disease activity assessments: a prospective study for incorporation of imaging in clinical trials.
    Clin Exp Rheumatol. 2016;34:802-807.
    PubMed     Text format     Abstract available


  102. SOLFIETTI L, Binello GB, Stella S, Bazzan M, et al
    Thrombin generation assay: interactions between chronic inflammation and haemostasis in patients with autoimmune diseases.
    Clin Exp Rheumatol. 2016;34:925-928.
    PubMed     Text format     Abstract available


  103. PINCUS T
    Electronic eRAPID3 (Routine Assessment of Patient Index Data): opportunities and complexities.
    Clin Exp Rheumatol. 2016;34.
    PubMed     Text format     Abstract available


  104. RICHTER A, Meissner Y, Strangfeld A, Zink A, et al
    Primary and secondary patient data in contrast: the use of observational studies like RABBIT.
    Clin Exp Rheumatol. 2016;34.
    PubMed     Text format     Abstract available


  105. PINCUS T
    Electronic multidimensional health assessment questionnaire (eMDHAQ): past, present and future of a proposed single data management system for clinical care, research, quality improvement, and monitoring of long-term outcomes.
    Clin Exp Rheumatol. 2016;34.
    PubMed     Text format     Abstract available


  106. ALETAHA D, Becede M, Smolen JS
    Information technology concerning SDAI and CDAI.
    Clin Exp Rheumatol. 2016;34.
    PubMed     Text format     Abstract available


  107. HUO Y, Veldhuizen RD, van der Heijde DM, Besselink NJ, et al
    Automated joint space width quantification of hand and wrist joints: a proof of concept study.
    Clin Exp Rheumatol. 2016;34.
    PubMed     Text format     Abstract available


  108. LEEB BF, Brezinschek HP, Rintelen B
    RADAI-5 and electronic monitoring tools.
    Clin Exp Rheumatol. 2016;34.
    PubMed     Text format     Abstract available


  109. SONG ST, Kim JJ, Lee S, Kim HA, et al
    Efficacy of tocilizumab therapy in Korean patients with adult-onset Still's disease: a multicentre retrospective study of 22 cases.
    Clin Exp Rheumatol. 2016;34.
    PubMed     Text format     Abstract available


    August 2016
  110. LEVITSKY A, Wick MC, Mottonen T, Leirisalo-Repo M, et al
    Early treatment intensification induces favourable radiographic outcomes according to predicted versus observed radiographic progression in early rheumatoid arthritis: a subanalysis of the randomised FIN-RACo and NEO-RACo trials.
    Clin Exp Rheumatol. 2016.
    PubMed     Text format     Abstract available


  111. KUBO S, Nakano K, Nakayamada S, Hirata S, et al
    Clinical, radiographic and functional efficacy of abatacept in routine care for rheumatoid arthritis patients: Abatacept Leading Trial for RA on Imaging Remission (ALTAIR) study.
    Clin Exp Rheumatol. 2016.
    PubMed     Text format     Abstract available


  112. FERRAZ-AMARO I, Lopez-Mejias R, Ubilla B, Genre F, et al
    Proprotein convertase subtilisin/kexin type 9 in rheumatoid arthritis.
    Clin Exp Rheumatol. 2016.
    PubMed     Text format     Abstract available


  113. KUUSALO LA, Puolakka KT, Kautiainen H, Alasaarela EM, et al
    Intra-articular glucocorticoid injections should not be neglected in the remission targeted treatment of early rheumatoid arthritis: a post hoc analysis from the NEO-RACo trial.
    Clin Exp Rheumatol. 2016.
    PubMed     Text format     Abstract available


  114. VAN DEN HOEK J, Roorda LD, Boshuizen HC, Tijhuis GJ, et al
    Trend in and predictors for cardiovascular mortality in patients with rheumatoid arthritis over a period of 15 years: a prospective cohort study.
    Clin Exp Rheumatol. 2016.
    PubMed     Text format     Abstract available


    July 2016
  115. YOSHIHARA H, Yoneoka D, Margalit A
    National trends and in-hospital outcomes in patients with rheumatoid arthritis undergoing elective atlantoaxial spinal fusion surgery.
    Clin Exp Rheumatol. 2016.
    PubMed     Text format     Abstract available


  116. ASAMI Y, Ishiguro H, Ueda A, Nakajima H, et al
    First report of membranous nephropathy and systemic lupus erythematosus associated with abatacept in rheumatoid arthritis.
    Clin Exp Rheumatol. 2016.
    PubMed     Text format     Abstract available


  117. VASSILOPOULOS D, Delicha EM, Settas L, Andrianakos A, et al
    Safety profile of repeated rituximab cycles in unselected rheumatoid arthritis patients: a long-term, prospective real-life study.
    Clin Exp Rheumatol. 2016.
    PubMed     Text format     Abstract available


  118. MILUTINOVIC S
    Reply to: Could this be the pioneering case of short-blanket syndrome? Filippou et al.
    Clin Exp Rheumatol. 2016;34:721.
    PubMed     Text format    


  119. FILIPPOU G, Bertoldi I, Frediani B
    Could this be the pioneering case of short-blanket syndrome? Comment on: Development of ultrasound enthesitis score to identify patients with enthesitis having spondyloarthritis: prospective, double-blinded, controlled study. Milutinovic et al. Clin E
    Clin Exp Rheumatol. 2016;34:721.
    PubMed     Text format    


  120. TYRSIN D, Chuvpilo S, Matskevich A, Nemenov D, et al
    From TGN1412 to TAB08: the return of CD28 superagonist therapy to clinical development for the treatment of rheumatoid arthritis.
    Clin Exp Rheumatol. 2016;34.
    PubMed     Text format     Abstract available


  121. AVCI AB, Feist E, Burmester GR
    Targeting GM-CSF in rheumatoid arthritis.
    Clin Exp Rheumatol. 2016;34.
    PubMed     Text format     Abstract available


  122. PALM O, Ueland T, Garen T, Michelsen AE, et al
    Endostatin is higher and associated with pulmonary involvement in primary Sjogren's syndrome.
    Clin Exp Rheumatol. 2016;34:690-3.
    PubMed     Text format     Abstract available


  123. VREJU FA, Filippucci E, Gutierrez M, Di Geso L, et al
    Subclinical ultrasound synovitis in a particular joint is associated with ultrasound evidence of bone erosions in that same joint in rheumatoid patients in clinical remission.
    Clin Exp Rheumatol. 2016;34:673-8.
    PubMed     Text format     Abstract available


  124. CAPALDO C, Carvajal Alegria G, Cornec D, Jousse-Joulin S, et al
    The active immunological profile in patients with primary Sjogren's syndrome is restricted to typically encountered autoantibodies.
    Clin Exp Rheumatol. 2016;34:722.
    PubMed     Text format    


  125. ASIKAINEN J, Nikiphorou E, Kaarela K, Lindqvist E, et al
    Is long-term radiographic joint damage different between men and women? Prospective longitudinal data analysis of four early RA cohorts with greater than 15 years follow-up.
    Clin Exp Rheumatol. 2016;34:641-5.
    PubMed     Text format     Abstract available


  126. LEE J, Koh JH, Kwok SK, Park SH, et al
    The EULAR Sjogren's Syndrome Patient-Reported Index is an independent determinant of health-related utility values of Korean patients with primary Sjogren's syndrome.
    Clin Exp Rheumatol. 2016;34:663-7.
    PubMed     Text format     Abstract available


  127. BARONE F, Colafrancesco S
    Sjogren's syndrome: from pathogenesis to novel therapeutic targets.
    Clin Exp Rheumatol. 2016;34.
    PubMed     Text format     Abstract available


    June 2016
  128. DETERT J, Dziurla R, Hoff P, Gaber T, et al
    Effects of treatment with etanercept versus methotrexate on sleep quality, fatigue and selected immune parameters in patients with active rheumatoid arthritis.
    Clin Exp Rheumatol. 2016.
    PubMed     Text format     Abstract available


  129. FRITSCH-STORK RD, Silva-Cardoso SC, Groot Koerkamp MJ, Broen JC, et al
    Expression of ERAP2 and LST1 is increased before start of therapy in rheumatoid arthritis patients with good clinical response to glucocorticoids.
    Clin Exp Rheumatol. 2016.
    PubMed     Text format     Abstract available


  130. CHE H, Combe B, Morel J, Cantagrel A, et al
    Performance of patient-reported outcomes in the assessment of rheumatoid arthritis disease activity:the experience of the ESPOIR cohort.
    Clin Exp Rheumatol. 2016.
    PubMed     Text format     Abstract available


  131. KAWASHIRI SY, Nishino A, Suzuki T, Nakashima Y, et al
    Rapid improvement of Clinical Disease Activity Index (CDAI) at 3 months predicts a preferable CDAI outcome at 1 year in active rheumatoid arthritis patients treated with tocilizumab: results from an observational investigation of daily clinical practi
    Clin Exp Rheumatol. 2016.
    PubMed     Text format     Abstract available


    May 2016
  132. PLASENCIA C, Wolbink G, Krieckaert CL, Kneepkens EL, et al
    Comparing a tapering strategy to the standard dosing regimen of TNF inhibitors in rheumatoid arthritis patients with low disease activity.
    Clin Exp Rheumatol. 2016.
    PubMed     Text format     Abstract available


  133. RODRIGUEZ-RODRIGUEZ L, Leon L, Lamas JR, Gomez A, et al
    Dose down-titration of biological DMARDs in patients with rheumatoid arthritis over time and in daily clinical practice.
    Clin Exp Rheumatol. 2016.
    PubMed     Text format     Abstract available


  134. AALTONEN KJ, Turunen JH, Sokka T, Puolakka K, et al
    A survey on the medication adherence to methotrexate among rheumatoid arthritis patients treated with self-administered biologic drugs.
    Clin Exp Rheumatol. 2016.
    PubMed     Text format     Abstract available


  135. WANG T, Zheng XJ, Ji YL, Liang ZA, et al
    Tumour markers in rheumatoid arthritis-associated interstitial lung disease.
    Clin Exp Rheumatol. 2016.
    PubMed     Text format     Abstract available


  136. BAGNATO GL, Fiorenza A, Cordova F, Roberts WN, et al
    Clinical, autoimmune, and psychiatric parameters correlate with sleep disturbance in patients with systemic sclerosis and rheumatoid arthritis.
    Clin Exp Rheumatol. 2016.
    PubMed     Text format     Abstract available


  137. HOLDEN SE, Currie CJ, Lennon M, Reynolds AV, et al
    Cost of dose escalation in people with rheumatoid arthritis treated with TNF inhibitors across Europe.
    Clin Exp Rheumatol. 2016.
    PubMed     Text format     Abstract available


  138. CALABRO A, Caterino AL, Elefante E, Valentini V, et al
    One year in review 2016: novelties in the treatment of rheumatoid arthritis.
    Clin Exp Rheumatol. 2016;34:357-72.
    PubMed     Text format     Abstract available


  139. PRIORI R, Minniti A, Antonazzo B, Fusconi M, et al
    Sleep quality in patients with primary Sjogren's syndrome.
    Clin Exp Rheumatol. 2016;34:373-9.
    PubMed     Text format     Abstract available


  140. VASKO R, Streich JH, Blaschke S, Muller GA, et al
    Vimentin fragments are potential markers of rheumatoid synovial fibroblasts.
    Clin Exp Rheumatol. 2016;34:513-20.
    PubMed     Text format     Abstract available


  141. PERTOVAARA M, Korpela M
    Regular physical activity is associated with lower levels of ESSPRI and other favourable patient-reported outcomes in patients with primary Sjogren's syndrome.
    Clin Exp Rheumatol. 2016;34:560.
    PubMed     Text format    


  142. ZABOTTI A, Salvin S, Quartuccio L, De Vita S, et al
    Differentiation between early rheumatoid and early psoriatic arthritis by the ultrasonographic study of the synovio-entheseal complex of the small joints of the hands.
    Clin Exp Rheumatol. 2016;34:459-65.
    PubMed     Text format     Abstract available


  143. SAKAIRI T, Hiromura K, Kaneko Y, Maeshima A, et al
    Histological findings in the spleen affected by adult-onset Still's disease: a report of three cases.
    Clin Exp Rheumatol. 2016;34:566-7.
    PubMed     Text format    


    April 2016
  144. RAYMOND AR, Brooksbank RL, Millen AM, Norton GR, et al
    Telomere length, endothelial activation and carotid atherosclerosis in black and white African patients with rheumatoid arthritis.
    Clin Exp Rheumatol. 2016.
    PubMed     Text format     Abstract available


  145. WALLENSTEIN GV, Kanik KS, Wilkinson B, Cohen S, et al
    Effects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis: results of two Phase 2 randomised controlled trials.
    Clin Exp Rheumatol. 2016.
    PubMed     Text format     Abstract available


  146. KREMER JM, Blanco R, Halland AM, Brzosko M, et al
    Clinical efficacy and safety maintained up to 5 years in patients with rheumatoid arthritis treated with tocilizumab in a randomised trial.
    Clin Exp Rheumatol. 2016.
    PubMed     Text format     Abstract available


  147. GUALTIEROTTI R, Ingegnoli F, Griffini S, Grovetti E, et al
    Prothrombotic biomarkers in patients with rheumatoid arthritis: the beneficial effect of IL-6 receptor blockade.
    Clin Exp Rheumatol. 2016.
    PubMed     Text format     Abstract available


  148. GONZALEZ-FERNANDEZ ML, Valor L, Morales-Lozano R, Hernandez-Florez D, et al
    To what extent is foot pain related to biomechanical changes and ultrasound-detected abnormalities in rheumatoid arthritis?
    Clin Exp Rheumatol. 2016.
    PubMed     Text format     Abstract available


  149. HOLMSTROM M, Koivuniemi R, Korpi K, Kaasalainen T, et al
    Cardiac magnetic resonance imaging reveals frequent myocardial involvement and dysfunction in active rheumatoid arthritis.
    Clin Exp Rheumatol. 2016.
    PubMed     Text format     Abstract available


  150. GENG Y, Han J, Deng X, Zhang Z, et al
    Deep clinical remission: an optimised target in the management of rheumatoid arthritis? Experience from an ultrasonography study.
    Clin Exp Rheumatol. 2016.
    PubMed     Text format     Abstract available


  151. YANG X, Wang M, Zhang X, Li X, et al
    Diagnostic accuracy of anti-RA33 antibody for rheumatoid arthritis: systematic review and meta-analysis.
    Clin Exp Rheumatol. 2016.
    PubMed     Text format     Abstract available


  152. LEE YH, Bae SC
    Vitamin D level in rheumatoid arthritis and its correlation with the disease activity: a meta-analysis.
    Clin Exp Rheumatol. 2016.
    PubMed     Text format     Abstract available


    March 2016
  153. MANARA M, Bianchi G, Bruschi E, Azzolini V, et al
    Adherence to current recommendations on the use of methotrexate in rheumatoid arthritis in Italy: results from the MARI study.
    Clin Exp Rheumatol. 2016.
    PubMed     Text format     Abstract available


  154. RONGEN-VAN DARTEL SA, Repping-Wuts H, Donders R, van Hoogmoed D, et al
    A multidimensional 'path analysis' model of factors explaining fatigue in rheumatoid arthritis.
    Clin Exp Rheumatol. 2016.
    PubMed     Text format     Abstract available


  155. NUSSLEIN HG, Alten R, Galeazzi M, Lorenz HM, et al
    Efficacy and prognostic factors of treatment retention with intravenous abatacept for rheumatoid arthritis: 24-month results from an international, prospective, real-world study.
    Clin Exp Rheumatol. 2016.
    PubMed     Text format     Abstract available


  156. HODGE JA, Kawabata TT, Krishnaswami S, Clark JD, et al
    The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis.
    Clin Exp Rheumatol. 2016.
    PubMed     Text format     Abstract available


  157. SARAUX A, Rouanet S, Flipo RM, Poncet JC, et al
    Glucocorticoid-sparing in patients suffering from rheumatoid arthritis and treated with tocilizumab: the SPARE-1 study.
    Clin Exp Rheumatol. 2016.
    PubMed     Text format     Abstract available


  158. RUIZ-LARRANAGA O, Uribarri M, Alcaro MC, Escorza-Trevino S, et al
    Genetic variants associated with rheumatoid arthritis patients and serotypes in European populations.
    Clin Exp Rheumatol. 2016.
    PubMed     Text format     Abstract available


  159. LOPALCO G, Vitale A, Iannone F, Cantarini L, et al
    Anakinra long-term efficacy and safety in the management of Schnitzler's syndrome and latent tuberculosis infection.
    Clin Exp Rheumatol. 2016;34:353.
    PubMed     Text format    


  160. CHOI BY, Oh HJ, Lee YJ, Song YW, et al
    Prevalence and clinical impact of fibromyalgia in patients with primary Sjogren's syndrome.
    Clin Exp Rheumatol. 2016;34.
    PubMed     Text format     Abstract available


  161. FERRO F, Vagelli R, Bruni C, Cafaro G, et al
    One year in review 2016: Sjogren's syndrome.
    Clin Exp Rheumatol. 2016;34:161-71.
    PubMed     Text format     Abstract available


  162. GALICIA-HERNANDEZ G, Parra-Salcedo F, Ugarte-Martinez P, Contreras-Yanez I, et al
    Sustained moderate-to-high disease activity and higher Charlson score are predictors of incidental serious infection events in RA patients treated with conventional disease-modifying anti-rheumatic drugs: a cohort study in the treat-to-target era.
    Clin Exp Rheumatol. 2016;34:261-9.
    PubMed     Text format     Abstract available


  163. MAUERMANN M, Hochauf-Stange K, Kleymann A, Conrad K, et al
    Parvovirus infection in early arthritis.
    Clin Exp Rheumatol. 2016;34:207-13.
    PubMed     Text format     Abstract available


  164. QUARTUCCIO L, Salvin S, Corazza L, Gandolfo S, et al
    Efficacy of belimumab and targeting of rheumatoid factor-positive B-cell expansion in Sjogren's syndrome: follow-up after the end of the phase II open-label BELISS study.
    Clin Exp Rheumatol. 2016;34:311-4.
    PubMed     Text format     Abstract available


  165. YOKOGAWA N, Lieberman SM, Sherry DD, Vivino FB, et al
    Features of childhood Sjogren's syndrome in comparison to adult Sjogren's syndrome: considerations in establishing child-specific diagnostic criteria.
    Clin Exp Rheumatol. 2016;34:343-51.
    PubMed     Text format     Abstract available


    February 2016
  166. TEJERA-SEGURA B, de Vera-Gonzalez AM, Lopez-Mejias R, Gonzalez-Gay MA, et al
    Serum cathepsin S and cystatin C: relationship to subclinical carotid atherosclerosis in rheumatoid arthritis.
    Clin Exp Rheumatol. 2016.
    PubMed     Text format     Abstract available


  167. SEBASTIANI M, Manfredi A, Cerri S, Della Casa G, et al
    Radiologic classification of usual interstitial pneumonia in rheumatoid arthritis-related interstitial lung disease: correlations with clinical, serological and demographic features of disease.
    Clin Exp Rheumatol. 2016.
    PubMed     Text format     Abstract available


  168. YOSHIHARA H, Yoneoka D, Margalit A, Zuckerman JD, et al
    Rheumatoid arthritis patients undergoing total hip and knee arthroplasty have better in-hospital outcomes compared with non-rheumatoid arthritis patients.
    Clin Exp Rheumatol. 2016.
    PubMed     Text format     Abstract available


  169. BERTHELOT JM, Sibilia J
    Rampant infections of bone marrow stem cell niches as triggers for spondyloarthropathies and rheumatoid arthritis.
    Clin Exp Rheumatol. 2016.
    PubMed     Text format     Abstract available


  170. RINALDI LA, Simoni D, Maresca M, Monaco V, et al
    Gait abnormalities in early rheumatoid arthritis with temporomandibular joint involvement.
    Clin Exp Rheumatol. 2016.
    PubMed     Text format     Abstract available


  171. IANNONE F, Tampoia M, Giannini M, Lopalco G, et al
    Changes in anti-cyclic citrullinated peptide antibodies and rheumatoid factor isotypes serum levels in patients with rheumatoid arthritis following treatment with different biological drugs.
    Clin Exp Rheumatol. 2016.
    PubMed     Text format     Abstract available


  172. REMUZGO-MARTINEZ S, Genre F, Lopez-Mejias R, Ubilla B, et al
    Decreased expression of methylene tetrahydrofolate reductase (MTHFR) gene in patients with rheumatoid arthritis.
    Clin Exp Rheumatol. 2016.
    PubMed     Text format     Abstract available


  173. SCOTT IC, Ibrahim F, Simpson G, Kowalczyk A, et al
    A randomised trial evaluating anakinra in early active rheumatoid arthritis.
    Clin Exp Rheumatol. 2016.
    PubMed     Text format     Abstract available


    January 2016
  174. FRAGOULIS GE, Stamopoulos P, Barbatis C, Tzioufas AG, et al
    Panniculitis: an unusual presenting manifestation of rheumatoid arthritis.
    Clin Exp Rheumatol. 2016.
    PubMed     Text format     Abstract available


  175. NAREDO E, Iagnocco A
    One year in review: ultrasound in arthritis.
    Clin Exp Rheumatol. 2016;34:1-10.
    PubMed     Text format     Abstract available


  176. VALIM V, Gerdts E, Jonsson R, Ferreira GA, et al
    Atherosclerosis in Sjogren's syndrome: evidence, possible mechanisms and knowledge gaps.
    Clin Exp Rheumatol. 2016;34:133-42.
    PubMed     Text format     Abstract available


  177. GUGGINO G, Ciccia F, Raimondo S, Giardina G, et al
    Invariant NKT cells are expanded in peripheral blood but are undetectable in salivary glands of patients with primary Sjogren's syndrome.
    Clin Exp Rheumatol. 2016;34:25-31.
    PubMed     Text format     Abstract available


    December 2015
  178. COLOMBO E, Scarsi M, Piantoni S, Tincani A, et al
    Serum levels of granzyme B decrease in patients with rheumatoid arthritis responding to abatacept.
    Clin Exp Rheumatol. 2015.
    PubMed     Text format     Abstract available


  179. VIZZARDI E, Bazzani C, Cavazzana I, Sciatti E, et al
    Prognostic value of diastolic dysfunction in asymptomatic rheumatoid arthritis patients without cardiovascular risk factors.
    Clin Exp Rheumatol. 2015.
    PubMed     Text format     Abstract available


    November 2015
  180. COHEN SB, Koenig A, Wang L, Kwok K, et al
    Efficacy and safety of tofacitinib in US and non-US rheumatoid arthritis patients: pooled analyses of phase II and III.
    Clin Exp Rheumatol. 2015.
    PubMed     Text format     Abstract available


  181. ANECCHINO C, Fanizza C, Marino V, Romero M, et al
    Drug outcome survey to evaluate anti-TNF treatment in rheumatoid arthritis: an Italian observational study (the DOSE study).
    Clin Exp Rheumatol. 2015.
    PubMed     Text format     Abstract available


  182. INANC N, Ozen G, Direskeneli H
    Predictive value of ultrasonographic assessment of disease activity in response to tumor necrosis factor-alpha inhibitor treatment in rheumatoid arthritis: a prospective cohort study.
    Clin Exp Rheumatol. 2015.
    PubMed     Text format     Abstract available


  183. FEDELE AL, Alivernini S, Gremese E, Ferraccioli G, et al
    CTLA-4 Ig as an effective treatment in a patient with type I diabetes mellitus and seropositive rheumatoid arthritis.
    Clin Exp Rheumatol. 2015.
    PubMed     Text format     Abstract available


  184. BARBIERI F, Zampogna G, Camellino D, Paparo F, et al
    Ankylosis of the wrist bones in patients with rheumatoid arthritis: a study with extremity-dedicated MRI.
    Clin Exp Rheumatol. 2015.
    PubMed     Text format     Abstract available


  185. CHEUNG PP, Guo Y, Lahiri M
    Predominance of large joint active synovitis in Asian patients with established rheumatoid arthritis.
    Clin Exp Rheumatol. 2015.
    PubMed     Text format     Abstract available


  186. YANG X, Gao F, Liu Y
    Association of homocysteine with immunological-inflammatory and metabolic laboratory markers and factors in relation to hyperhomocysteinaemia in rheumatoid arthritis.
    Clin Exp Rheumatol. 2015;33:900-3.
    PubMed     Text format     Abstract available


  187. IDOLAZZI L, Adami S, Capozza R, Bianchi G, et al
    Suboptimal methotrexate use in rheumatoid arthritis patients in Italy: the MARI study.
    Clin Exp Rheumatol. 2015;33:895-9.
    PubMed     Text format     Abstract available


  188. MILUTINOVIC S, Radunovic G, Veljkovic K, Zlatanovic M, et al
    Development of ultrasound enthesitis score to identify patients with enthesitis having spondyloarthritis: prospective, double-blinded, controlled study.
    Clin Exp Rheumatol. 2015;33:812-7.
    PubMed     Text format     Abstract available


  189. BALCI MA, Pamuk ON, Pamuk GE, Uzundere FK, et al
    Epidemiology and outcome of adult-onset Still's disease in Northwestern Thrace region in Turkey.
    Clin Exp Rheumatol. 2015;33:818-23.
    PubMed     Text format     Abstract available


  190. CHEN SY, Shiau AL, Wu CL, Wang CR, et al
    Amelioration of experimental arthritis by intra-articular injection of an epidermal growth factor receptor tyrosine kinase inhibitor.
    Clin Exp Rheumatol. 2015;33:839-43.
    PubMed     Text format     Abstract available


    September 2015
  191. ATISHA-FREGOSO Y, Rivera-Vicencio Y, Banos-Pelaez M, Hernandez-Molina G, et al
    Main causes and risk factors for hospitalisation in patients with primary Sjogren's syndrome.
    Clin Exp Rheumatol. 2015;33:721-5.
    PubMed     Text format     Abstract available


  192. UNGPRASERT P, Srivali N, Kittanamongkolchai W
    Risk of venous thromboembolism in patients with Sjogren's syndrome: a systematic review and meta-analysis.
    Clin Exp Rheumatol. 2015;33:746-50.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Rheumatoid Arthritis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: